• Blog
  • Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report

    Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report

    Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report
    Report code - SR1781 Delivery - 2 Weeks
    Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, Share &a See more...

    Market Insights

    The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is estimated to grow from USD 4.4 billion in 2020 to USD 6.7 billion by 2026 at a healthy CAGR of 7.2% during the forecast period.

    Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market- Research Scope

    Base Year of Study

    2020

    Trend Period

    2015-2019

    Forecast Period

    2021-2026

    Market Size in 2020

    US$ 4.4 billion

    Market Size in 2026

    US$ 6.7 billion

    Market Growth (2021-2026)

    7.2% CAGR

     

    Fig.: Exocrine Pancreatic Insufficiency Therapeutics and Diagnostics Market Size, 2020-26

    Wish to get a free sample? Register Here

    What is Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics?

    Exocrine pancreatic insufficiency is a condition, wherein, the food is not digested properly due to insufficient levels of digestive enzymes from the pancreas. It is also referred to as EPI and is commonly present in humans, who are affected with coachman-Diamond Syndrome and cystic fibrosis. Exocrine pancreatic insufficiency is commonly caused by the loss of pancreatic cells that produces the digestive enzymes. The symptoms of exocrine pancreatic insufficiency vary from fatigue, diarrhea, weight loss, etc.

    Covid-19 Impact Analysis

    The COVID-19 pandemic has moderately affected the Exocrine Pancreatic Insufficiency (EPI) therapeutics and diagnostics industry. Also, social distancing, limited access to clinics, lockdown of the population, that has led to a slow-down in patient flow & referrals The focus of healthcare professionals has been shifted toward the treatment of COVID-19-infected patients, which affected the treatment of non-emergency medical conditions, amid the pandemic.

    Key Players

    Key players operating in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market are-

    • Allergan plc (Ireland)
    • Digestive Care, Inc (US)
    • Nordmark Arzneimittel GmbH & Co. KG (Germany)
    • AzurRx Biopharma, Inc. (US)
    • AbbVie, Inc (US)
    • Anthera Pharmaceuticals, Inc. (US)
    • Janssen Pharmaceuticals, Inc. (Belgium)
    • Cilian AG (Germany)

    Market Dynamics

    The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is majorly driven by rising incidences of exocrine pancreatic insufficiency worldwide, surging demand for advanced therapeutics, and presence of large number of pipeline drugs. Also, growing awareness regarding this rare condition and its negative impact on the health further augments the product demand. Moreover, rising prevalence of cystic fibrosis and chronic pancreatitis further bolsters the industry growth, during the review period.

    Segments Analysis

    Application Trends

    Based on application, the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market has been classified into nutritional management and Pancreatic enzyme replacement therapy (PERT), Life style modifications approach. The Pancreatic enzyme replacement therapy (PERT) segment accounted for the largest market share in 2020 due to its status as the traditional therapy. Also, PERT exhibits high efficacy, efficiency, and potency in terms of treatment.

    Regional Trends

    By region, the North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market accounted the highest share of around 35% in 2020 and is expected to grow at a robust CAGR during the review period. The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market growth is mainly attributed to changing lifestyle of the people, rising incidence of lifestyle-associated factors, increasing prevalence of digestion problems, and unhealthy dietary habits augments the regional market growth during the forecast timeline.

    The Asia Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is expected to grow at the healthy CAGR during the review period due to changing lifestyles and eating habits, rising aging population in countries like Japan, high consumption of junk food, and increasing disposable income, further bolsters the regional market growth.

    Critical Questions Answered in the Report

    This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market. The historic years considered for the study are 2016-2019, base year is 2020, estimated year is 2021, and forecast period is 2022-2026. Following are the critical questions answered in the report.

    • What are the key trends in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in next five years?
    • What is the impact of COVID-19 on global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market?
    • What are the key strategies adopted by the major vendors to lead in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market?
    • What is the market share of the top vendors?

    Target Audience

    The target audience of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market includes-

    • Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Vendors
    • Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Manufacturers
    • Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Distributors
    • Organizations
    • Government Bodies.

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is estimated to grow from USD 4.4 billion in 2020 to USD 6.7 billion by 2026 at a healthy CAGR of 7.2% during the forecast period.

    Key players operating in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market are- Allergan plc (Ireland), Digestive Care, Inc (US), Nordmark Arzneimittel GmbH & Co. KG (Germany), AzurRx Biopharma, Inc. (US), AbbVie, Inc (US), Anthera Pharmaceuticals, Inc. (US), Janssen Pharmaceuticals, Inc. (Belgium), Cilian AG (Germany).

    The Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is majorly driven by rising incidences of exocrine pancreatic insufficiency worldwide, surging demand for advanced therapeutics, and presence of large number of pipeline drugs.

    North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market accounted the highest share of around 35% in 2020 and is expected to grow at a robust CAGR during the review period.

    The target audience of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market includes- Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Vendors, Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Manufacturers, Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Distributors, Organizations, Government Bodies.